SCHEMBL14720394

SCHEMBL14720394

CC(C)NCC1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.48
PKM P14618 1/20 0.48
EPHX1 P07099 1/20 0.47
IDO1 P14902 1/20 0.47
TDO2 P48775 1/20 0.47
HPGD P15428 1/20 0.46
ACKR3 P25106 1/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
BRD3 Q15059 1/20 0.45
NR1H2 P55055 1/20 0.43
NPC1 O15118 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GPR119 Q8TDV5 2/20 0.43
KDM1A O60341 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8263565 1.00 KDM4E (0.48) KDM4EPKMEPHX1IDO1TDO2
SCHEMBL14003362 1.00 KDM4E (0.48) KDM4EPKMEPHX1IDO1TDO2
SCHEMBL17776649 0.93 ACKR3 (0.52) EPHX1HPGDACKR3ALDH1A1MAPT
SCHEMBL13059914 0.92 KDM4E (0.56) KDM4EPKMEPHX1HPGDALDH1A1
SCHEMBL24392671 0.88 NAMPT (0.52) KDM4EPKMEPHX1HPGDACKR3
SCHEMBL4314752 0.86 KDM4E (0.48) KDM4EPKMEPHX1IDO1TDO2
SCHEMBL4314564 0.86 KDM4E (0.48) KDM4EPKMEPHX1IDO1TDO2
SCHEMBL13202625 0.84 KDM4E (0.51) KDM4EPKMEPHX1IDO1TDO2
SCHEMBL15061680 0.84 KDM4E (0.51) KDM4EPKMEPHX1IDO1TDO2
SCHEMBL3273916 0.84 KDM4E (0.51) KDM4EPKMEPHX1IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806346-B2 HTT modulators for treating Huntington's disease CHDI FOUNDATION, INC. (US) 2023-11-07 US disclosed
CN-116997548-A HTT modulators for the treatment of huntington's disease CHDI基金会股份有限公司 2023-11-03 CN disclosed
EP-4149937-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI Foundation, Inc. (US) 2023-03-22 EP disclosed
US-20220409615-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI FOUNDATION, INC. 2022-12-29 US disclosed
WO-2013028445-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409615-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 KDM4E 3315/4885PKM 3417/4885EPHX1 4091/4885
US-11806346-B2 HTT modulators for treating Huntington's disease HTT, HYPK, ATXN2 KDM4E 3315/4885PKM 3417/4885EPHX1 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.